Chemotherapy-nave patients with stage III , stage IV , or recurrent NSCLC age 70 years with a performance status of 0 or 1 who were considered unsuitable for bolus cisplatin administration were randomly assigned to receive docetaxel 60 mg/m ( 2 ) on day 1 , every 3 weeks , or docetaxel 20 mg/m ( 2 ) plus cisplatin 25 mg/m ( 2 ) on days 1 , 8 , and 15 , every 4 weeks .